CoChat

Antidepressant activity of fingolimod in mice

Open access
di Nuzzo, Luigi, Orlando, Rosamaria, Tognoli, Cristina, Di Pietro, Paola, Bertini, Giuseppe, Miele, Jessica, Bucci, Domenico, Motolese, Marta, Scaccianoce, Sergio, Caruso, Alessandra, Mauro, Gianluca, De Lucia, Carmine, Battaglia, Giuseppe, Bruno, Valeria, Fabene, Paolo Francesco, Nicoletti, Ferdinando · 2015 · Pharmacology Research & Perspectives
Cited by 55

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Recent findings indicate that fingolimod, the first oral drug approved for the treatment of multiple sclerosis (MS), acts as a direct inhibitor of histone deacetylases (HDAC s) and enhances the production of brain‐derived neurotrophic factor (BDNF) in the CNS. Both mechanisms are relevant to the pathophysiology and treatment of major depression. We examined the antidepressant activity of fingolimod in mice subjected to chronic unpredictable stress (CUS), a model of reactive depression endowed with face and pharmacological validity. Chronic treatment with fingolimod (3 mg kg−1, i.p., once a day for 4 weeks) reduced the immobility time in the forced swim test (FST) in a large proportion of CUS mice. This treatment also caused anxiogenic‐like effects in the social interaction test without affecting anxiety‐like behavior in the elevated plus maze or spatial learning in the water maze. CUS mice showed reduced BDNF levels and enhanced HDAC 2 levels in the hippocampus. These changes were reversed by fingolimod exclusively in mice that showed a behavioral response to the drug in the FST. Fingolimod treatment also enhanced H3 histone K14‐acetylation and adult neurogenesis in the hippocampus of CUS mice. Fingolimod did not affect most of the parameters we have tested in unstressed control mice. The antidepressant‐like activity of fingolimod was confirmed in mice chronically treated with corticosterone. These findings show for the first time that fingolimod exerts antidepressant‐like effect acting in a “disease‐dependent” manner, and raise the interesting possibility that the drug could relieve depressive symptoms in MS patients independently of its disease‐modifying effect on MS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/prp2.135

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 55

Metadata

Authors
di Nuzzo, L., Orlando, R., Tognoli, C., Di Pietro, P., Bertini, G., Miele, J., Bucci, D., Motolese, M., Scaccianoce, S., Caruso, A., Mauro, G., De Lucia, C., Battaglia, G., Bruno, V., Fabene, P. F., & Nicoletti, F.
Venue
Pharmacology Research & Perspectives
Publisher
Wiley
Published
2015-05-24
Volume
3
Issue
3
Pages
e00135-e00135
ISSN
2052-1707 (ISSN-L)
OpenAlex
W1543741818
Cited by
55
References
21
FWCI
3.38
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antidepressant activity of fingolimod in mice. https://app.cochat.ai/papers/10.1002/prp2.135
The paper
di Nuzzo, L., Orlando, R., Tognoli, C., Di Pietro, P., Bertini, G., Miele, J., Bucci, D., Motolese, M., Scaccianoce, S., Caruso, A., Mauro, G., De Lucia, C., Battaglia, G., Bruno, V., Fabene, P. F., & Nicoletti, F. (2015). Antidepressant activity of fingolimod in mice. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.135

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.